Mitochondrial Toxicity Studied with the PBMC of Children from the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Liu, Kai ^a,b   Sun, Yu ^a   Liu, Daojie ^a,b   Yin, Jiming ^a,b   Qiao, Luxin ^b   Shi, Ying ^a   Dong, Yaowu ^c   Li, Ning ^a,b   Zhang, Fujie ^c   Chen, Dexi ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Institute of Hepatology   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; DIDANOSINE; LACTIC ACID; LAMIVUDINE; MESSENGER RNA; MITOCHONDRIAL DNA; NELFINAVIR; NEVIRAPINE; RIBONUCLEOTIDE REDUCTASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE KINASE; THYMIDINE KINASE 2; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CELL FUNCTION; CHILD; CHINESE; CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL TOXICITY; NUCLEOTIDE SEQUENCE; P53R2 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SCHOOL CHILD; TK2 GENE;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CHINA; DNA, MITOCHONDRIAL; FEMALE; HIV INFECTIONS; HUMANS; LACTIC ACID; MALE; MITOCHONDRIA; MONOCYTES; MUTATION; OXIDATIVE PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84874542854     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057223     Document Type: Article

References (33)

1. Pinti M, Salomoni P, Cossarizza A, (2006) Anti-HIV drugs and the mitochondria. Biochim Biophys Acta 1757: 700-707.
2. Lewis W, Dalakas MC, (1995) Mitochondrial toxicity of antiviral drugs. Nat Med 1: 417-422.
3. Lewis W, Copeland WC, Day BJ, (2001) Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 81: 777-790.
4. Kakuda TN, (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22: 685-708.
5. Kohler JJ, Lewis W, (2007) A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 48: 166-172.
6. Lo JC, Kazemi MR, Hsue PY, Martin JN, Deeks SG, et al. (2005) The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 41: 1335-1340.
7. Eriksson S, Xu B, Clayton DA, (1995) Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase. J Biol Chem 270: 18929-18934.
8. Lewis W, Day BJ, Copeland WC, (2003) Copeland, Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2: 812-822.
9. Rampazzo C, Fabris S, Franzolin E, Crovatto K, Frangini M, et al. (2007) Mitochondrial thymidine kinase and the enzymatic network regulating thymidine triphosphate pools in cultured human cells. J Biol Chem 282: 34758-34769.
10. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, et al. (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42-49.
11. Zhou S, Zhao Y, He Y, Li H, Bulterys M, et al. (2010) Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009. J Acquir Immune Defic Syndr 54: 191-196.
12. Mambo E, Gao X, Cohen Y, Guo Z, Talalay P, et al. (2003) Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A 100: 1838-1843.
13. ter Hofstede HJ, Willems HL, Koopmans PP, (2004) Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers. J Clin Virol 29: 44-50.
14. Gajewski CD, Yang L, Schon EA, Manfredi G, (2003) New insights into the bioenergetics of mitochondrial disorders using intracellular ATP reporters. Mol Biol Cell 14: 3628-3635.
15. Wu Y, Li N, Zhang T, Wu H, Huang C, et al. (2009) Mitochondrial DNA base excision repair and mitochondrial DNA mutation in human hepatic HuH-7 cells exposed to stavudine. Mutat Res 664: 28-38.
16. Wong LJ, Perng CL, Hsu CH, Bai RK, Schelley S, et al. (2003) Compensatory amplification of mtDNA in a patient with a novel deletion/duplication and high mutant load. J Med Genet 40: e125.
17. Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, et al. (2007) Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 39: 776-780.
18. Kollberg G, Darin N, Benan K, Moslemi AR, Lindal S, et al. (2009) A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. Neuromuscul Disord 19: 147-150.
19. Nolan D, S Mallal, (2004) Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 9: 849-863.
20. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, et al. (2003) Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. Aids 17: 1769-1785.
21. Herman JS, Easterbrook PJ (2001) The metabolic toxicities of antiretroviral therapy. Int J STD AIDS 12: 555-562; quiz 563-564.
22. Brinkman K, Kakuda TN, (2000) Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 13: 5-11.
23. Yamanaka H, Gatanaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, et al. (2007) Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 195: 1419-1425.
24. European Paediatric Lipodystrophy Group (2004) Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. Aids 18: 1443-1451.
25. Cossarizza A, Pinti M, Moretti L, Bricalli D, Bianchi R, et al. (2002) Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis 185: 299-305.
26. Scruggs ER, Dirks Naylor AJ, (2008) Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 82: 83-88.
27. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, et al. (2007) Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 46: 318-322.
28. Papp E, Gadawski I, Côté HC, (2008) Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells. J Antimicrob Chemother 61: 1048-1052.
29. Thelander L, (2007) Ribonucleotide reductase and mitochondrial DNA synthesis. Nat Genet 39: 703-704.
30. Sun R, Eriksson S, Wang L, (2010) Identification and characterization of mitochondrial factors modulating thymidine kinase 2 activity. Nucleosides Nucleotides Nucleic Acids 29: 382-385.
31. Vilà MR, Segovia-Silvestre T, Gámez J, Marina A, Naini AB, et al. (2003) Reversion of mtDNA depletion in a patient with TK2 deficiency. Neurology 60: 1203-1205.
32. Pérez-Pérez MJ, Priego EM, Hernández AI, Familiar O, Camarasa MJ, et al. (2008) Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future. Med Res Rev 28: 797-820.
33. Götz A, Isohanni P, Pihko H, Paetau A, Herva R, et al. (2008) Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain 131: 2841-2850.